Major surgery increases serum levels of vascular endothelial growth factor only temporarily

被引:25
作者
Bondestam, J
Salven, P
Jääskelä-Saari, H
Ikonen, T
Lepäntalo, M
Mattila, S
Joensuu, H
机构
[1] Univ Helsinki, Cent Hosp, Dept Oncol, HYKS, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol, FIN-00029 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Surg, FIN-00029 Helsinki, Finland
基金
芬兰科学院;
关键词
D O I
10.1016/S0002-9610(99)00253-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Vascular endothelial growth factor (VEGF) is a hypoxia-induced endothelial cell-specific mitogen, which is angiogenic in vivo and up-regulated in several malignancies. VEGF can be used as a prognostic marker, but the effect of surgical trauma on serum VEGF (S-VEGF) concentrations is unknown and might reduce the value of VEGF as a serum marker. METHODS: We monitored S-VEGF levels by enzyme-linked immunosorbent assay in patients undergoing surgery. RESULTS: Eighteen patients with major surgery had slightly elevated S-VEGF compared with the preoperative level (median 9.5 pg/mL) on the first (median 35 pg/mL; P = 0.0002) and third (median 19 pg/mL; P = 0.004) postoperative day, but not in later samples. The levels measured in 8 patients after minor surgery did not differ from the preoperative levels (P = 0.14). CONCLUSIONS: Even major surgery is associated only with a slight and transient increase in S-VEGF levels, and, therefore, is unlikely to interfere markedly with the use of VEGF as a prognostic marker. (C) 2000 by Excerpta Medica, Inc.
引用
收藏
页码:57 / 59
页数:3
相关论文
共 11 条
  • [1] UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION INDUCED BY MYOCARDIAL-ISCHEMIA - IMPLICATIONS FOR CORONARY ANGIOGENESIS
    BANAI, S
    SHWEIKI, D
    PINSON, A
    CHANDRA, M
    LAZAROVICI, G
    KESHET, E
    [J]. CARDIOVASCULAR RESEARCH, 1994, 28 (08) : 1176 - 1179
  • [2] Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing
    Corral, CJ
    Siddiqui, A
    Wu, LC
    Farrell, CL
    Lyons, D
    Mustoe, TA
    [J]. ARCHIVES OF SURGERY, 1999, 134 (02) : 200 - 205
  • [3] Dirix LY, 1996, ANN ONCOL, V7, P843
  • [4] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [5] FREEMAN MR, 1995, CANCER RES, V55, P4140
  • [6] A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
    Salven, P
    Teerenhovi, L
    Joensuu, H
    [J]. BLOOD, 1997, 90 (08) : 3167 - 3172
  • [7] Salven P, 1998, INT J CANCER, V79, P144, DOI 10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO
  • [8] 2-T
  • [9] Salven P, 1999, CLIN CANCER RES, V5, P487
  • [10] VASCULAR-PERMEABILITY FACTOR (VPF, VEGF) IN TUMOR BIOLOGY
    SENGER, DR
    VANDEWATER, L
    BROWN, LF
    NAGY, JA
    YEO, KT
    YEO, TK
    BERSE, B
    JACKMAN, RW
    DVORAK, AM
    DVORAK, HF
    [J]. CANCER AND METASTASIS REVIEWS, 1993, 12 (3-4) : 303 - 324